Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-149-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2009-01-08 till 2009-06-05
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline-conform study under GLP without deviations
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Guidelines for Screening Toxicity Testing of Chemicals: Testing Methods for New Substances, enacted July 13, 1974, amended December 5, 1986
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Details on test material:
- - public name of test material:
Reaction mass of 6,13-dichloro-3,10-bis{[2-({[(2-chloroethyl)sulfonyl]alkanoyl}amino)ethyl]-amino}- polycarboheterocyclo 4,11-disulfonic acid, mono and/or disodium salt and 6,13-dichloro-3-{[2-({[(2-chloroethyl)sulfonyl]alkanoyl}amino) ethyl]amino}-10-[(2-{[4-(ethenylsulfonyl)alkanoyl]amino}ethyl)amino] polycarboheterocyclo -4,11-disulfonic acid, mono and/or di sodium salt
- Physical state: solid, dark blue powder
- Analytical purity: approx. 86.6%
- Lot/batch No.: VER 2108 BOP 02/07
- Expiration date of the lot/batch: November 30, 2012
- Storage condition of test material: At room temperature at about 20 °C
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS: Rat, HanRcc: WIST(SPF)
- Source: Harlan Laboratories Ltd., Laboratory Animal Services, Wölferstrasse 4, 4414 Füllinsdorf / Switzerland
- Age at study initiation: ca. 7 weeks at delivery
- Weight at study initiation: at Acclimatization: Males: 177 g to 198 g (mean 189 g) Females: 139 g to 156 g (mean 146 g)
- Fasting period before study:
- Housing:
- Diet (e.g. ad libitum): Pelleted standard Kliba Nafag 3433 (batch no. 61/08) rat / mouse maintenance diet (Provimi Kliba SA, 4303 Kaiseraugst / Switzerland) was available ad libitum
- Water (e.g. ad libitum): Community tap-water from Itingen was available ad libitum in water bottles.
- Acclimation period: 7d
Acclimatization: Under test conditions after health examination. Only animals without any visible signs of illness were used.
- Randomization: Computer-generated random algorithm
- Accommodation: In groups of five in Makrolon type-4 cages with wire mesh tops and standard softwood bedding (‘Lignocel’ Schill AG, 4132 Muttenz / Switzerland).
ENVIRONMENTAL CONDITIONS
- Temperature (°C): temp. range: 22 ± 3 °C
- Humidity (%): relative humidity range: 30 - 70%)
- Air changes (per hr): Air-conditioned with 10 - 15 air changes per hour
- Photoperiod (hrs dark / hrs light): There was 12-hour fluorescent light/12-hour dark cycle with music during the light period.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- bidistilled
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The dose formulations were prepared weekly
- Mixing appropriate amounts with (Type of food): test material was weighed into a glass beaker on a tared Mettler balance. Thereafter the remaining vehicle was added. The mixtures were stirred using a magnetic stirrer and stored at room temperature (15 - 25 °C). Homogeneity of the test item in the vehicle was maintained during the daily administration period using a magnetic stirrer.
The dose formulations were stored in glass beakers at room temperature (20 ± 5 °C).
Based upon the results of dose formulation analyses performed during a non-GLP dose range finding study (Harlan Laboratories Study C19567), the stability of the test item formulations was considered to be sufficient to justify weekly preparation. These analyses were repeated under GLP for this study.
VEHICLE
- Justification for use and choice of vehicle (if other than water): water
- Concentration in vehicle: 0, 5, 20 and 100 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- After experimental start, samples of the control group as well as three samples (top, middle and bottom) of about 2 g of each concentration were taken prior to dosing for analysis of homogeneity and concentration and stability. Samples of about 2 g of each concentration were taken during week 3 after commencement of dosing to confirm homogeneity and concentration.
The samples were delivered at ambient temperature to the Analytical Department and then stored at -20 ± 5 °C until analysis. The analysis was performed using a HPLC method provided by the Sponsor. The test item was used as analytical standard.
This analytical part was conducted at Harlan Laboratories Ltd., Itingen, Switzerland under GLP¬compliant conditions to verify the identity of the test item test material administered and to determine the content, homogeneity and stability of application formulations.
Several application formulations were prepared and representative analytical samples were collected and dispatched to the analytical laboratories internally. The test item concentrations were determined by HPLC coupled to a UV detector and quantified with the area under the peak.
The identity of test material was confirmed by its peak retention times which were similar to that measured in the working standards. The test item content in all samples was found to be within the accepted range of ±20% of the nominal content. In addition, the homogeneous distribution of test material in bi-distilled water was demonstrated. The application formulations were considered to be stable for at least 7 days when kept at room temperature.
In conclusion, the results obtained within this part confirm the correct preparation and storage of application formulations during the conduct of this study. - Duration of treatment / exposure:
- 28 d
- Frequency of treatment:
- once daily, 7d/wk
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 50, 200 and 1000 mg/kg/day
Basis:
actual ingested
- No. of animals per sex per dose:
- Group 1: 0 mg/kg/day 10 males 10 females
Group 2: 50 mg/kg/day 5 males 5 females
Group 3: 200 mg/kg/day 5 males 5 females
Group 4: 1000 mg/kg/day 10 males 10 females
Reserve animals:
Group 10: 1 male and 1 female - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:The dose levels were selected based on a previous dose range finding toxicity study in Wistar rats (Harlan Laboratories Study C19567).
- Rationale for animal assignment (if not random):Computer-generated random algorithm
- Rationale for selecting satellite groups:Toxicity testing (termination after 28 treatment days) resp Recovery testing (termination after an additional 14-day recovery period)
- Post-exposure recovery period in satellite groups: 14 d - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
- Cage side observations checked (see table 1) were included.
DETAILED CLINICAL OBSERVATIONS: yes
- Time schedule: once before administration and once weekly (week 1-3)
The animals were observed for clinical signs once before commencement of administration as well as twice daily on days 1 to 3, once daily on days 4-28 (treatment period), and once daily during days 1 to 14 (recovery period).
DETAILED BEHAVIORAL OBSERVATIONS: yes
- Time schedule: once before administration and once weekly (week 1-3)
The animals were observed in their home cages, outside their home cages in a standard arena and in the hand. These observations were performed once before commencement of administration and once weekly (weeks 1 to 3) thereafter.
BODY WEIGHT: Yes
Body weights were recorded weekly during acclimatization, treatment and recovery periods and before necropsy, using an on-line electronic recording system consisting of a Mettler balance connected to the Harlan Laboratories computer
FOOD CONSUMPTION:
The food consumption was recorded once during the acclimatization period and weekly thereafter, using an on-line electronic recording system consisting of a Mettler balance connected to the Harlan Laboratories computer.
FOOD EFFICIENCY:
- Body weight gain : data: relative food consumption (g/kg body weight/day)
OPHTHALMOSCOPIC EXAMINATION: Yes , see table 1
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after 4 weeks (satellite A and B), after 6 weeks satellite B
Blood samples were drawn from the retro-orbital plexus from all animals under light isoflurane anesthesia. The animals were fasted in metabolism cages for approximately 18 hours before blood sampling but allowed access to water ad libitum. The samples were collected early in the working day to reduce biological variation caused by circadian rhythms. Blood samples were drawn from the retro-orbital plexus using a micro-hematocrit glass capillary tube.
- How many animals: all animals
- Parameters checked in table 3 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after 4 weeks (satellite A and B), after 6 weeks satellit B
Blood samples were drawn from the retro-orbital plexus from all animals under light isoflurane anesthesia. The animals were fasted in metabolism cages for approximately 18 hours before blood sampling but allowed access to water ad libitum. The samples were collected early in the working day to reduce biological variation caused by circadian rhythms. Blood samples were drawn from the retro-orbital plexus using a micro-hematocrit glass capillary tube.
- How many animals: all animals
- Parameters checked in table 4 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine:Urine was collected during the 18 hours fasting period into a specimen vial, using a metabolism
cage.
- Parameters checked in table 5 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes, see table 1
- Time schedule for examinations:During week 4, relevant parameters from a modified Irwin screen test were evaluated in all animals.
- Dose groups that were examined: see table 1
- Battery of functions tested: reflexes / grip strength / locomotor activity
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, see table 2
HISTOPATHOLOGY: Yes, see table 2 - Statistics:
- The following statistical methods were used to analyze body weight, grip strength, locomotor activity, clinical laboratory data, organ weights and ratios as well as macroscopic findings:
• The Dunnett-test (many to one t-test) based on a pooled variance estimate was applied if the variables could be assumed to follow a normal distribution for the comparison of the treated groups and the control groups for each sex.
• The Steel-test (many-one rank test) was applied instead of the Dunnett-test when the data could not be assumed to follow a normal distribution.
• Fisher's exact-test
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- Minor differences in the mean locomotor activity, but considered not to be related to the test item
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- some discolaration, considerdto be related to the test item
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Viability / Mortality
All animals survived until scheduled necropsy.
Detailed Clinical Observations (Weekly)
No findings of toxicological relevance were noted during the Detailed Clinical Observations (weeks 1-3).
BODY WEIGHT AND WEIGHT GAIN
After the treatment period, no test item-related differences in the mean body weights or mean body weight gain values were noted at any dose level. Differences noted during recovery in the mean body weights of females previously treated with the test item were, in the absence of changes during treatment, considered to be unrelated to the test item.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
The mean daily food consumption of the test item-treated rats compared favorably with those of the controls.
OPHTHALMOSCOPIC EXAMINATION
General Cageside Observations (Daily)
Dark feces was noted in males and females of all test item-treated groups. The speed of onset and the mean severity of this finding were related to dose. Although this is a test item-related finding, it is considered to be common following oral administration of dyestuffs and of no toxicological relevance.
No clinical findings of adverse nature were seen at any dose level.
SUMMARY Clinical Laboratory Investigations
Hematology / Clinical Biochemistry / Urinalysis
After four weeks’ treatment, no differences of toxicological relevance were noted at any dose
level. All differences remained within the ranges of the historical control data, were doseunrelated,
were largely due to aberrant control values, or were not accompanied by concomitant
changes in related parameters and therefore considered to be incidental.
After two weeks’ recovery, none of the observed differences were considered to be late effects.
HAEMATOLOGY
After four weeks’ treatment, the differences noted in a small number of parameters attained statistical significance when compared with the respective control values, but remained within the ranges of the historical control data, were dose-unrelated, were largely due to aberrant control values, or were not accompanied by concomitant changes in related parameters and therefore considered to be incidental.
After two weeks’ recovery, none of the observed differences had been seen at the end of the treatment period, and remained within the ranges of the historical control data. These were not considered to be late effects.
CLINICAL CHEMISTRY
After four weeks’ treatment, males and females treated with 1000 mg/kg/day had elevated glucose levels (p<0.05 and p<0.01, respectively) and elevated total bilirubin (p<0.01 and p<0.05, respectively) when compared with the controls. The latter difference exceeded the upper limit of the respective historical control data. These isolated differences were considered to be unrelated to the test item treatment.
The mean triglyceride level of females treated with 1000 mg/kg/day was significantly lower (p<0.01) than that of the control females, but remained within the lower limit of the historical control data.
Some differences were incurred by outliers in individual control animals, or by general differences in the control values when compared with the historical control data. For example, although the mean triglyceride level for males treated with 1000 mg/kg/day was markedly lower than that of the control males, this was due to a single outlier in the control group (male no. 3).
Males treated with 1000 mg/kg/day and 200 mg/kg/day had significantly elevated potassium levels (p<0.01 and p<0.05, respectively) but the differences were largely considered to be due to a low control value, and were unrelated to the treatment. All other differences were doseunrelated or were not accompanied by concomitant changes in related parameters and therefore considered to be incidental.
After two weeks’ recovery, there was a small number of differences when compared with the controls. All remained within the ranges of the historical control values, and none of the differences were seen after the treatment period. Hence they were considered to be incidental.
There were no differences of toxicological relevance in the clinical biochemistry parameters of females.
URINALYSIS
After four weeks’ treatment, the differences noted in a small number of urinalysis parameters were significantly higher than those of the respective control values, but remained within the ranges of the historical control data or were not accompanied by concomitant changes in related parameters and therefore considered to be incidental. Staining of the urine samples was considered to be related to the excretion of the test item via the renal pathway.
After two weeks’ recovery, there were no differences of toxicological relevance when compared with the controls.
NEUROBEHAVIOUR
Functional Observational Battery
No findings of toxicological relevance were noted during the Functional Observational Battery (week 4).
Grip Strength
The mean fore- and hindlimb grip strength of the test item-treated rats compared favorably with those of the respective controls.
Locomotor Activity
Males treated with 1000 mg/kg/day had significantly elevated locomotor activity during the 0-10 minute measurement interval (p<0.05). No other differences were noted in males, and females at this dose were unaffected.
At 50 mg/kg/day, the mean locomotor activity was significantly elevated in females from 10-20 minutes (p<0.05) and from 20-30 minutes (p<0.05). A similar difference was noted in the total locomotor activity (0-60 minutes, p<0.05) of the females. In the absence of similar changes at 200 mg/kg/day, these differences were considered to be incidental.
ORGAN WEIGHTS
The organs from satellite A and B animals were weighed before fixation and recorded on the scheduled dates of necropsy. Relative organ weights were calculated on the basis of the body weight and brain weight.
The terminal body weight was recorded immediately prior to necropsy and the organ to terminal
body weight ratios as well as organ to brain weight ratios were determined.
GROSS PATHOLOGY
Organ Weights
(See Summary Tables on p. , Individual Tables on p. )
No test item-related effects upon the mean absolute or relative organ weights were noted.
At 1000 mg/kg/day, the mean absolute and relative organ weights compared favorably with those of the control rats after fours weeks of treatment.
At 200 mg/kg/day, the mean absolute and relative adrenal weights of males were significantly reduced (p<0.05) when compared with the controls. This finding was considered to be unrelated to the test item as the control value was skewed by a single outlying value (male no. 2). Females at this dose level had significantly elevated (p<0.05) liver-to-body weight ratio and significantly reduced (p<0.05) thymus-to-body weight ratio. The mean spleen-to-brain weight ratio of females was significantly reduced (p<0.05) after four weeks of treatment. These findings, in the absence of changes at the higher dose, were considered to be incidental.
At 50 mg/kg/day, the mean absolute adrenal weight was significantly reduced (p<0.05) when compared with the controls. This finding was considered to be unrelated to the test item as the control value was skewed by a single outlying value (male no. 2).
After the recovery period, the mean absolute liver weights and mean absolute spleen weights were significantly reduced (p<0.05 and p<0.01, respectively) in females previously treated with 1000 mg/kg/day. The mean brain-to-body weight ratio was significantly elevated (p<0.01) in these females, whereas the mean heart-, liver-, and spleen-to-brain weight ratios were all significantly reduced (p<0.01, p<0.05 and p<0.01, respectively) when compared with controls. These differences were not seen at the end of the treatment period and were not considered to be late effects of the test item.
Macroscopic Findings
After four weeks of treatment, dark discoloration of several organs (tongue, stomach, jejunum, ileum, cecum, colon, rectum, kidneys, and mesenteric lymph nodes) was noted at several dose levels and considered to be related to the test item.
Other macroscopical findings (accentuated lobular pattern in one male at 1000 mg/kg/day, reddish discoloration of the pancreas in one male at 200 mg/kg/day, foci on the mandibular lymph nodes of one male treated with 200 mg/kg/day) occurred at low incidence and were considered to be typical background changes unrelated to the treatment with the test item.
After two weeks of recovery, dark discoloration of the kidneys persisted in all animals and was considered to be effects of the test item. Dark red foci were noted on the stomach of one male, an isolated dark brown focus was noted on the lungs of one male and one female, reddish discoloration of the ileum was seen in one female, and a minor ear injury was recorded in one female.
HISTOPATHOLOGY: NON-NEOPLASTIC
All organ and tissue samples (as defined in the table 2) were processed, embedded and cut at an approximate thickness of 2 to 4 micrometers and stained with hematoxylin and eosin.
Slides of all organs and tissues (as defined in the table 2) which were collected at scheduled sacrifices from all animals of the control and high-dose groups and all gross lesions from all animals were examined by the study pathologist. Organ and tissue samples taken from animals which died spontaneously or which were killed in extremis were evaluated similarly to those organs taken from animals of the high-dose group.
As test item-related morphologic changes were detected in the organs of high-dose animals, the same organs (kidneys) from animals of the mid- and low-dose groups were examined.
A description of all abnormalities is included in the pathology report. Attempts were made to correlate gross observations with microscopic findings.
Microscopic Findings
No microscopical findings of toxicological relevance were noted in animals necropsied after four weeks of treatment. After two weeks of recovery, blue pigment (engulfed in pulmonary phagocytes) were noted in three animals. All lesions recorded during the microscopic investigation were within the range of background alterations that may be recorded in this type of study, and in rats of this strain and age.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Body Weight Males
Group 1 |
Group 2 |
Group 3 |
Group 4 |
|
0 mg/kg |
50 mg/kg |
200 mg/kg |
1000 mg/kg |
|
ACCLIMATIZATION |
|
|
|
|
Day 1 MEAN |
189 |
188 |
188 |
188 |
ST.DEV. |
7 |
7 |
6 |
7 |
MINIMUM |
177 |
179 |
181 |
178 |
MAXIMUM |
198 |
197 |
194 |
196 |
N |
10 |
5 |
5 |
10 |
TREATMENT PERIOD |
|
|
|
|
Day 1 MEAN |
233 |
231 |
229 |
229 |
ST.DEV. |
8 |
8 |
6 |
8 |
MINIMUM |
218 |
221 |
221 |
213 |
MAXIMUM |
241 |
240 |
236 |
242 |
N |
10 |
5 |
5 |
10 |
Day 8 MEAN |
269 |
271- |
261- |
267 |
ST.DEV. |
11 |
11 |
8 |
11 |
MINIMUM |
244 |
261 |
252 |
246 |
MAXIMUM |
281 |
287 |
271 |
287 |
N |
10 |
5 |
5 |
10 |
Day 15 MEAN |
298 |
299 |
288 |
298 |
ST.DEV. |
15 |
15 |
10 |
15 |
MINIMUM |
269 |
287 |
277 |
276 |
MAXIMUM |
318 |
323 |
301 |
326 |
N |
10 |
5 |
5 |
10 |
Day 22 MEAN |
323 |
319 |
311 |
318- |
ST.DEV. |
19 |
16 |
10 |
17 |
MINIMUM |
290 |
305 |
300 |
292 |
MAXIMUM |
356 |
347 |
326 |
345 |
N |
10 |
5 |
5 |
10 |
Day 28 MEAN |
342 |
332 |
325 |
336 |
ST.DEV. |
21 |
19 |
13 |
20 |
MINIMUM |
309 |
319 |
309 |
313 |
MAXIMUM |
381 |
366 |
343 |
369 |
N |
10 |
5 |
5 |
10 |
RECOVERY PERIOD |
|
|
|
|
Day 1 MEAN |
323 |
--- |
--- |
318 |
ST.DEV. |
19 |
--- |
--- |
14 |
MINIMUM |
293 |
--- |
--- |
298 |
MAXIMUM |
346 |
--- |
--- |
331 |
N |
5 |
0 |
0 |
5 |
Day 8 MEAN |
358 |
--- |
--- |
348 |
ST.DEV. |
24 |
--- |
--- |
22 |
MINIMUM |
322 |
--- |
--- |
320 |
MAXIMUM |
391 |
--- |
--- |
379 |
N |
5 |
0 |
0 |
5 |
Day 14 MEAN |
374 |
--- |
--- |
361 |
ST.DEV. |
25 |
--- |
--- |
21 |
MINIMUM |
338 |
--- |
--- |
337 |
MAXIMUM |
408 |
--- |
--- |
393 |
N |
5 |
0 |
0 |
5 |
Body Weight Females
Group 1 |
Group 2 |
Group 3 |
Group 4 |
|
0 mg/kg |
50 mg/kg |
200 mg/kg |
1000 mg/kg |
|
ACCLIMATIZATION |
|
|
|
|
Day 1 MEAN |
147 |
145 |
145 |
147 |
ST.DEV. |
4 |
4 |
4 |
5 |
MINIMUM |
143 |
141 |
141 |
141 |
MAXIMUM |
154 |
151 |
151 |
156 |
N |
10 |
5 |
5 |
10 |
TREATMENT PERIOD |
|
|
|
|
Day 1 MEAN |
171 |
167 |
167 |
165 |
ST.DEV. |
6 |
5 |
5 |
10 |
MINIMUM |
164 |
162 |
162 |
144 |
MAXIMUM |
180 |
173 |
173 |
180 |
N |
10 |
5 |
5 |
10 |
Day 8 MEAN |
187 |
186 |
186 |
184 |
ST.DEV. |
9 |
8 |
8 |
10 |
MINIMUM |
173 |
174 |
174 |
164 |
MAXIMUM |
200 |
195 |
195 |
198 |
N |
10 |
5 |
5 |
10 |
Day 15 MEAN |
206 |
203 |
203 |
200 |
ST.DEV. |
8 |
9 |
9 |
9 |
MINIMUM |
194 |
190 |
190 |
183 |
MAXIMUM |
216 |
212 |
212 |
215 |
N |
10 |
5 |
5 |
10 |
Day 22 MEAN |
218 |
211 |
211 |
212 |
ST.DEV. |
9 |
10 |
10 |
11 |
MINIMUM |
203 |
199 |
199 |
193 |
MAXIMUM |
231 |
222 |
222 |
228 |
N |
10 |
5 |
5 |
10 |
Day 28 MEAN |
224 |
221 |
221 |
221 |
ST.DEV. |
11 |
13 |
13 |
11 |
MINIMUM |
206 |
198 |
198 |
202 |
MAXIMUM |
240 |
233 |
233 |
236 |
N |
10 |
5 |
5 |
10 |
RECOVERY PERIOD |
|
|
|
|
Day 1 MEAN |
223 |
--- |
--- |
203 |
ST.DEV. |
10 |
--- |
--- |
13 |
MINIMUM |
210 |
--- |
--- |
193 |
MAXIMUM |
231 |
--- |
--- |
220 |
N |
5 |
0 |
0 |
5 |
Day 8 MEAN |
242 |
--- |
--- |
222 |
ST.DEV. |
13 |
--- |
--- |
12 |
MINIMUM |
226 |
--- |
--- |
211 |
MAXIMUM |
253 |
--- |
--- |
240 |
N |
5 |
0 |
0 |
5 |
Day 14 MEAN |
253 |
--- |
--- |
232 |
ST.DEV. |
9 |
--- |
--- |
13 |
MINIMUM |
243 |
--- |
--- |
221 |
MAXIMUM |
262 |
--- |
--- |
249 |
N |
5 |
0 |
0 |
5 |
Applicant's summary and conclusion
- Conclusions:
- Based on the results of this study, a no-observed-effect-level (NOEL) for test material could not be established, but the no-observed-adverse-effect-level (NOAEL) was considered to be 1000 mg/kg body weight/day.
- Executive summary:
In this subacute toxicity study, test material was administered daily by oral gavage to SPF-bredWistar rats of both sexes at dose levels of 50, 200 and 1000 mg/kg body weight/day for a period of 28 days. A control group was treated similarly with the vehicle, bidistilled water, only.
The groups comprised 5 animals per sex which were sacrificed after 28 days of treatment.Additional 5 rats per sex and group were used at 0 and 1000 mg/kg. These animals were treated for 28 days and then allowed a 14-day treatment-free recovery period after which they weresacrificed.
Clinical signs, outside cage observation, food consumption and body weights were recordedperiodically during pretest, the treatment and recovery periods. Functional observational battery,locomotor activity and grip strength were performed during week 4.
At the end of the dosing and the treatment-free recovery period, blood samples were withdrawnfor hematology and plasma chemistry analyses. Urine samples were collected for urinalyses. Allanimals were killed, necropsied and examined post mortem. Histological examinations wereperformed on organs and tissues from all control and high dose animals, and all gross lesionsfrom all animals.
From the animals of the low and middle dose groups, kidneys were examined to establish a no-effect level.
Mortality / Viability
All animals survived until scheduled necropsy.
Clinical Signs (Daily and Weekly)
Dark feces were observed with dose-related speed of onset and mean severity. Although this wasa test item-related finding, it was considered to be common following oral administration ofdyestuffs and of no toxicological relevance.
No findings of toxicological relevance were noted during the Detailed Clinical Observations(weeks 1-3).
Functional Observational Battery
No findings of toxicological relevance were noted during the Functional Observational Battery(week 4).
Grip Strength
The mean fore- and hindlimb grip strength of the test item-treated rats compared favorably with those of the respective controls.
Locomotor Activity
Minor differences in the mean locomotor activity were considered to be unrelated to the test item.
Food Consumption
The mean daily food consumption of the test item-treated rats compared favorably with those of the controls.
Body Weights
No test item-related differences in the mean body weights or mean body weight gain values werenoted at any dose level.
Clinical Laboratory Investigations
Hematology / Clinical Biochemistry / Urinalysis
After four weeks’ treatment, no differences of toxicological relevance were noted at any doselevel. All differences remained within the ranges of the historical control data, were dose-unrelated, were largely due to aberrant control values, or were not accompanied by concomitantchanges in related parameters and therefore considered to be incidental.
After two weeks’ recovery, none of the observed differences were considered to be late effects.
Organ Weights
No test item-related effects upon the mean absolute or relative organ weights were noted.
Macroscopic / Microscopic Findings
After four weeks of treatment, dark discoloration of several organs (tongue, stomach, jejunum,ileum, cecum, colon, rectum, kidneys, and mesenteric lymph nodes) was noted macroscopicallyat various dose levels and considered to be related to the test item.
After two weeks of recovery, persistent dark discoloration of the kidneys was noted in previouslytreated rats.
Microscopically, no findings of toxicological relevance were noted in animals necropsied after four weeks of treatment. After two weeks of recovery, blue pigment (engulfed in pulmonaryphagocytes) were noted in three animals.
CONCLUSION
Based on the results of this study, a no-observed-effect-level (NOEL) for test material could
not be established, but the no-observed-adverse-effect-level (NOAEL) was considered to be
1000 mg/kg body weight/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Napriek tomu, že agentúra ECHA poskytuje online veľa materiálov vo vašom jazyku, časť tejto stránky je k dispozícii len v anglickom jazyku. Viac informácií o praxi v oblasti viacjazyčnosti v agentúre ECHA.
Internetová stránka agentúry ECHA Stránka nie je plne podporovaná v prehliadači Internet Explorer 7 (a starších verziách). Aktualizujte si prehliadač Internet Explorer na novšiu verziu.
Táto webová lokalita využíva súbory cookies, aby sme vám zabezpečili najlepšie používateľske prostredie na našich webových stránkach.
Viac informácií ako využívame súbory cookies.